Peer-Reviewed Publications by Michael Har-Noy Ph.D.

For the official Immunovative Therapies, Ltd. corporate website, please visit www.immunovative.co.il

Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with utologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine.

Epple LM, Bemis LT, Cavanaugh RP, Skope A, Mayer-Sonnenfeld T, Frank C, Olver CS, Lencioni AM, Dusto NL, Tal A, Michael Har-Noy,* Lillehei KO, Katsanis E, Graner MW.

Int J Hyperthermia. 2013 Jun 20. [Epub ahead of print]

PMID:23786302[PubMed – as supplied by publisher]

*Founder and CEO of Immunovative Therapies, Ltd.

Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL’s unique structure: CRCL vaccine proteome leads to unique structure.

Mayer-Sonnenfeld T, Michael Har-Noy,* Lillehei KO, Graner MW.

Int J Hyperthermia. 2013 Jun 4. [Epub ahead of print]

PMID:23734882[PubMed – as supplied by publisher]

*Founder and CEO of Immunovative Therapies, Ltd.

 

 Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism.

LaCasse CJ, Janikashvili N, Larmonier CB, Alizadeh D, Hanke N, Kartchner J, Situ E, Centuori S, Michael Har-Noy,* Bonnotte B, Katsanis E, Larmonier N.

J Immunol. 2011 Dec 15;187(12):6310-7. doi: 10.4049/jimmunol.1101812. Epub 2011 Nov 9.

PMID:22075702[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

 Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia.

Janikashvili N, LaCasse CJ, Larmonier C, Trad M, Herrell A, Bustamante S, Bonnotte B, Michael Har-Noy,*  Larmonier N, Katsanis E.

Blood. 2011 Feb 3;117(5):1555-64. doi: 10.1182/blood-2010-06-288621. Epub 2010 Dec 1.

PMID:21123824[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

 Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma.

Michael Har-Noy,*  Zeira M, Weiss L, Fingerut E, Or R, Slavin S.

Leuk Res. 2009 Apr;33(4):525-38. doi: 10.1016/j.leukres.2008.08.017. Epub 2008 Oct 1.

PMID:18834631[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

 Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity.

Michael Har-Noy,* Zeira M, Weiss L, Slavin S.

Leuk Res. 2008 Dec;32(12):1903-13. doi: 10.1016/j.leukres.2008.05.007. Epub 2008 Jun 18.

PMID:18565579[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?

Michael Har-Noy,* Slavin S.

Med Hypotheses. 2008;70(6):1186-92. Epub 2007 Dec 3.

PMID:18054441[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

Cannabidiol lowers incidence of diabetes in non-obese diabetic mice.

Weiss L, Zeira M, Reich S, Michael Har-Noy,* Mechoulam R, Slavin S, Gallily R.

Autoimmunity. 2006 Mar;39(2):143-51.

PMID:16698671[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

The growth of cells with LAK activity in an automated tissue culture system (Acusyst P).

Alter BJ, Ochoa AC, Gruenberg(Har-Noy) ML,* Keyport GM, Bach FH.

Prog Clin Biol Res. 1987;244:301-11. No abstract available.

PMID:3498955[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

Modulatory action of FSH on LH-induced follicular growth in rats.

Peluso JJ, Luttmer S, Gruenberg (Har-Noy) ML.*

J Reprod Fertil. 1984 Sep;72(1):173-7.

PMID:6433010[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

Role of LH pulse amplitude in controlling rat ovarian oestradiol-17 beta secretion in vitro.

Peluso JJ, Downey MC, Gruenberg (Har-Noy) ML.*

J Reprod Fertil. 1984 May;71(1):107-12.

PMID:6427453[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

Regulation of ovarian follicular growth and steroidogenesis by low-amplitude LH pulses.

Peluso JJ, Gruenberg (Har-Noy) ML,* Steger RW.

Am J Physiol. 1984 Feb;246(2 Pt 2):R184-9.

PMID:6696143[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

The effect of an LH pulse on 3H-thymidine incorporation into cultured ovaries of metestrous rats.

Peluso JJ, Durkee T, Gruenberg (Har-Noy) ML.*

Cell Tissue Res. 1984;238(1):159-63.

PMID:6435878[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

Follicular development, steroidogenesis and ovulation within ovaries exposed in vitro to hormone levels which mimic those of the rat estrous cycle.

Gruenberg (Har-Noy) ML,* Steger RW, Peluso JJ.

Biol Reprod. 1983 Dec;29(5):1265-75.

PMID:6418225[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

Capacity of fertilized ova from mature and middle-aged rats to undergo preimplantation development in vitro.

Peluso JJ, Karey K, Gruenberg (Har-Noy) ML.*

Cell Tissue Res. 1983;229(2):451-6.

PMID:6850756[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.